# FITC-Labeled Human HLA-A\*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein



Description	
Source	Recombinant FITC-Labeled Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.
	It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide.
Accession	AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGAVGVGK
Molecular Weight	The protein has a predicted MW of 50.3 kDa. Due to glycosylation, the protein migrates to 51-65 kDa based on Tris-Bis PAGE result.
Wavelength	Excitation Wavelength: 490 nm
	Emission Wavelength: 520 nm
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE
	> 95% as determined by HPLC

## Formulation and Storage

Formulation Supplied as 0.22µm filtered solution in PBS (pH 7.4).


Storage Valid for 12 months from date of receipt when stored at -80°C.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

## **Background**

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

### **Assay Data**

#### Tris-Bis PAGE




**SEC-HPLC** 

FITC-Labeled Human HLA-A\*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

MHC-HM421F Cat. No.

## **Assay Data**



The purity of FITC-Labeled Human HLA-A\*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer is greater than 95% as determined by SEC-HPLC.